Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals

奥美沙坦 氨氯地平 医学 耐受性 血压 固定剂量组合 钙通道阻滞剂 联合疗法 药理学 替米沙坦 硝苯地平 二氢吡啶 内科学 泌尿科 不利影响 钙
作者
JAN N. BASILE
出处
期刊:Integrated blood pressure control [Dove Medical Press]
卷期号:3: 91-91 被引量:6
标识
DOI:10.2147/ibpc.s9691
摘要

Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals Jan BasileProfessor of Medicine, Medical University of South Carolina, Charleston, SC, USAAbstract: Hypertension remains a significant health burden in the United States, with almost one in three adults affected, and is an independent risk factor for cardiovascular and renal disease. The goal of antihypertensive treatment is to reduce cardiovascular and renal morbidity and mortality by reducing blood pressure (BP). Guidelines recommend a target BP of <140/90 mmHg, with a more stringent goal of <130/80 mmHg for patients with diabetes and chronic renal disease. However, BP goal attainment rates remain low and most patients require therapy with two or more antihypertensive agents. Combination antihypertensive therapy usually employs agents from different classes, thus benefitting from complementary mechanisms of action to achieve greater BP control with fewer side effects. Patient adherence to therapy is enhanced by formulating treatments as fixed-dose (single-pill) combinations. One example is the combination of amlodipine, a dihydropyridine calcium channel blocker (CCB), with olmesartan medoxomil, an angiotensin receptor blocker (ARB). Here, the rationale for the use of CCB/ARB combination therapy is discussed, as well as the pharmacology and tolerability of the amlodipine/olmesartan medoxomil combination and its efficacy in terms of achieving BP goal in patients with hypertension. Advantages of its use from the patient’s perspective are also discussed.Keywords: amlodipine, angiotensin receptor blockers, calcium channel blockers, fixed-dose combination therapy, hypertension, olmesartan medoxomil
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘘_别吵完成签到 ,获得积分10
刚刚
1秒前
3秒前
头铁老常发布了新的文献求助10
3秒前
英吉利25发布了新的文献求助10
4秒前
4秒前
wan完成签到,获得积分10
5秒前
积极从蕾发布了新的文献求助10
5秒前
夸克酱关注了科研通微信公众号
6秒前
6秒前
6秒前
醉意拥桃枝完成签到 ,获得积分10
8秒前
情怀的应助被头铁老常采纳,获得10
8秒前
共享精神的应助被牧百川采纳,获得10
9秒前
科研通AI65的应助被老实蛟凤采纳,获得10
9秒前
香蕉觅云的应助被米糊采纳,获得10
10秒前
Maestro_S的应助被米糊采纳,获得30
10秒前
xxdwyd发布了新的文献求助10
10秒前
科研通AI6.3的应助被米糊采纳,获得10
10秒前
科研通AI6.3的应助被米糊采纳,获得10
10秒前
英姑的应助被米糊采纳,获得10
11秒前
乐乐的应助被米糊采纳,获得10
11秒前
11秒前
Maestro_S的应助被米糊采纳,获得30
11秒前
11秒前
12秒前
爱笑的阿满完成签到,获得积分10
12秒前
12秒前
Ava的应助被哈哈镜阿姐采纳,获得10
12秒前
lmy的应助被睡个好觉采纳,获得10
13秒前
Firsterchao的应助被czy采纳,获得10
15秒前
汪家友发布了新的文献求助10
16秒前
17秒前
dianhuaxue发布了新的文献求助10
17秒前
Owen的应助被米糊采纳,获得10
18秒前
orixero的应助被米糊采纳,获得30
18秒前
赘婿的应助被米糊采纳,获得10
18秒前
Maestro_S的应助被米糊采纳,获得10
18秒前
汉堡包的应助被米糊采纳,获得10
18秒前
香蕉觅云的应助被米糊采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259